• Loading stock data…

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

[#item_full_content]

Print Friendly, PDF & Email
Spread the word